Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven

OTCPK:ARLZQ - Post by User

Old API Wind-down Ltd - Ordinary Shares > No bump before report

<< Previous

Bullboard Posts

Next >>

Comment by kuatoliveson Mar 13, 2017 1:16pm

110 Views

Post# 25971923

RE:RE:RE:No bump before report

The risk, IMO, is skyrocketing. If they can't uptake Yosprala fast enough to pay for all of the new sales consultants, 2017's loss might be more than 25 Million. A couple years of this and its cash crunch time. Plus they have to pump a bunch of money into Zontivity to re-launch which won't be done until June, according to Adams. And while the price they paid for that drug is relatively low, there's more risk if Zontivity uptake doesn't respond differently then it did for Merck. This is more than I can handle.

<< Previous

Bullboard Posts

Next >>

Mullen Group: Navigates market challenges towards success